OCT 10, 2019 12:00 PM PDT

Tumor Mutation Burden: Challenges and opportunities of measuring and interpreting tumor mutational burden for patient care

Sponsored by: QIAGEN
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Associate Professor, Pathology; Associate Director, Residency Program; Medical Director, Cytogenetics Laboratory AUMC.
    Biography
      Currently, Dr.Ravindra Kolhe is an Associate Professor in the Department of Pathology at the Augusta University in Augusta, Georgia, and divides his time between directing Molecular Pathology, Cytogenetics, Breast Pathology, teaching, and research. He is the CLIA laboratory director for the Georgia Esoteric & Molecular Labs and also serves as the Medical Director for the Cytogenetics Laboratory. As a Molecular and Genetic Pathologist, he is actively engaged in molecular and cytogenetic evaluation of patient samples as a part of the multi- disciplinary clinical team treating patients in a personalized and precision medicine model. As a Breast Pathologist, he provides expert opinions for the breast multidisciplinary tumor boards, consultation and second opinion to difficult breast cancer patients referred to Georgia Cancer Center. Dr. Kolhe is an physician-scientist with expertise in basic mechanisms of tumor immunology, including tolerogenic DCs, Tregs, and the indoleamine 2,3-dioxygenase pathway He has over 160 publications, including peer-reviewed articles, abstracts and invited reviews most in the realm of the molecular pathology of various malignancies.

    Abstract

    Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation load increases the likelihood that immunogenic neoantigens expressed by tumor cells may induce a response to immunotherapy.  However, TMB estimation and reporting can be heavily influenced by differing working processes across clinical and research laboratories; primarily, the choice of assay, platform, and how the assay is implemented and interpreted. To streamline and standardize this process at scale, QIAGEN offers an end to end solution, from detection to interpretation of TMB and other somatic alterations.

    In this webinar, we will provide insights into the implementation of the QIAseq Tumor Mutational Burden (TMB) Panel in the molecular diagnostics lab. This comprehensive cancer panel is capable of interrogating TMB, microsatellite instability (MSI), and other actionable alterations in a single assay, using specialized chemistry to remove false positives. Subsequently, we will discuss how QIAGEN Clinical Insight Interpret can streamline insights from comprehensive cancer profiles to deliver actionable information on detected variants and immunotherapy biomarkers, such as tumor mutational burden (TMB) and microsatellite instability (MSI). We will also discuss the concordance of the automatic implementation of the AMP/ASCO/CAP guidelines with manual expert classifications.


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    OCT 08, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    Loading Comments...
    Show Resources
    Attendees
    • See more